X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, FUJIFILM Diosynth Biotechnologies will provide drug substance manufacturing of efgartigimod (Vyvgart) at its large-scale biomanufacturing facility in Hillerod, Denmark.
Lead Product(s): Efgartigimod
Therapeutic Area: Immunology Product Name: Vyvgart
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Argenx
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 27, 2022
Details:
Novavax has been suffering from lower-than-expected demand for its COVID-19 vaccine (Nuvaxovid). Because of which Novavax will pay Fujifilm Diosynth Biotechnologies in a settlement tied to the "termination of manufacturing activity" at its CDMO partner.
Lead Product(s): NVX-CoV2373,Matrix-M1
Therapeutic Area: Infections and Infectious Diseases Product Name: Nuvaxovid
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Novavax
Deal Size: $185.0 million Upfront Cash: Undisclosed
Deal Type: Termination September 30, 2022
Details:
FUJIFILM will provide Atara with access to the flexible capacity and specific capability needed to manufacture clinical and commercial-stage allogeneic cell therapies for its promising pipeline, including tabelecleucel (tab-cel®), ATA188, and allogeneic CAR T therapies.
Lead Product(s): Tabelecleucel
Therapeutic Area: Immunology Product Name: Tab-cel
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Atara Biotherapeutics
Deal Size: Undisclosed Upfront Cash: $100.0 million
Deal Type: Partnership April 04, 2022
Details:
Under the agreement with FUJIFILM, will acquire Atara’s T-Cell Operations and Manufacturing facility. Atara with access to the flexible capacity needed to manufacture clinical and commercial stage allogeneic cell therapies for its pipeline, including tabelecleucel (tab-cel®).
Lead Product(s): Tabelecleucel
Therapeutic Area: Immunology Product Name: Tab-cel
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Recipient: Atara Biotherapeutics
Deal Size: $100.0 million Upfront Cash: $100.0 million
Deal Type: Partnership January 26, 2022
Details:
Under the terms of the agreement, FUJIFILM Diosynth Biotechnologies will support process development and scale up of ATYR1923, including the manufacture of bulk drug substance for additional clinical trials in ILD.
Lead Product(s): ATYR1923
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: ATYR1923
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: aTyr Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 30, 2021
Details:
FUJIFILM's site in Billingham, UK will manufacture antigen component of NVX-CoV2373, Novavax' COVID-19 vaccine candidate. Billingham plans to begin production of the first batch at beginning of Q1, 2021.
Lead Product(s): NVX-COV2373,Matrix-M
Therapeutic Area: Infections and Infectious Diseases Product Name: NVX-COV2373
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Novavax
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Expanded Partnership August 17, 2020
Details:
FUJIFILM Diosynth Biotechnologies' College Station, Texas, site will support COVID-19 vaccine manufacturing, and Speed up U.S. government program to begin delivering millions of doses of COVID-19 vaccine to U.S. population.
Lead Product(s): NVX-COV2373,Matrix-M
Therapeutic Area: Infections and Infectious Diseases Product Name: NVX-COV2373
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: BARDA
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 03, 2020
Details:
FUJIFILM Diosynth will support COVID-19 vaccine candidate manufacturing, as part of Operation Warp Speed, a U.S. government program that aims to begin delivering millions of doses of a safe, effective vaccine for COVID-19 to the U.S. population.
Lead Product(s): NVX-COV2373,Matrix-M
Therapeutic Area: Infections and Infectious Diseases Product Name: NVX-COV2373
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: U.S Government
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 27, 2020
Details:
The Agreement aims to manufacture bulk drug substance for NVX-CoV2373, Novavax’ COVID-19 vaccine candidate. FDB’s site in Morrisville, North Carolina has begun production of the first batch of NVX-CoV2373.
Lead Product(s): NVX-COV2373,Matrix-M
Therapeutic Area: Infections and Infectious Diseases Product Name: NVX-COV2373
Highest Development Status: Phase IProduct Type: Vaccine
Recipient: Novavax
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 23, 2020
Details:
Avigan (favipiravir) is an antiviral medication largely used to treat influenza in Japan. It was approved in the country in 2014 and became a generic drug in 2019.
Lead Product(s): Favipiravir
Therapeutic Area: Infections and Infectious Diseases Product Name: Avigan
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Dr. Reddy\'s Laboratories
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 21, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
